Post-earnings recap
Reported
Thu, May 7, 2026
EPS actual
$-0.76
EPS est.
$-0.90
EPS surprise
+15.84%
1-day move
-23.41%
Insmed's earnings report showed a smaller-than-expected loss per share, which was a positive surprise. However, the lack of revenue reporting and the significant drop in stock price indicate investor concerns about the company's performance and future outlook. The 23.41% decline in stock price suggests that investors are reacting negatively to the overall uncertainty surrounding the company's financial health.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.76 | $-0.99 | +15.84% |
| Revenue | — | $302M | — |
No transcript is on record, and the analysis is based on numerical results only.
Insmed Incorporated is a biotechnology company focused on developing innovative therapies for patients with serious and rare diseases. Operating in the health care sector, Insmed's work is particularly relevant as the demand for specialized treatments continues to grow.
Last quarter
In Q4 2025, Insmed reported an EPS of $-1.54, which was significantly worse than the expected $-1.07. Following the announcement, the stock rose by 6.54% the next day, indicating some investor optimism despite the miss.
EPS beat streak
2Q
EPS beat rate
25%
Avg EPS surprise
-3.23%
Avg 1-day reaction
+2.89%
Analysts expect Insmed to report a loss of $-0.99 per share with revenues around $302 million. Given the company's recent performance, there is a mix of cautious optimism and concern regarding its ability to meet these expectations.
Bull case
If Insmed can exceed the EPS estimate and show strong revenue growth, it could signal a turnaround in its financial performance, boosting investor confidence.
Bear case
Conversely, if the company fails to meet these estimates again, it may raise concerns about its long-term viability and lead to further declines in stock price.
Key metrics to watch
EPS
$-0.99Earnings per share is crucial for understanding the company's profitability and financial health.
Revenue
$302MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will Insmed's revenue meet or exceed the consensus estimate of $302 million?
Revenue performance is critical to assessing the company's market position and growth potential, especially after recent misses.
Q2
What specific strategies is management implementing to improve EPS from the expected $-0.99?
Understanding management's approach to addressing profitability will be key for investors concerned about ongoing losses.
—
Est. EPS
$-0.76
Est. Rev
$192M
Impl. Move
±7.5%
Why consensus could be wrong
The consensus may underestimate Insmed's potential for revenue growth due to recent product developments that have not been fully factored into estimates.
Supporting evidence
The stock has shown resilience with positive reactions despite earnings misses, suggesting underlying strength.
Options pricing indicates a significant expected move, which could reflect investor sentiment that is more optimistic than consensus estimates.
Key risk
If revenue comes in significantly above $302 million, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter's results will be pivotal in determining whether Insmed can stabilize its financial performance after a series of misses.
Bull confirmed if
Achieving an EPS of better than $-0.99 and revenue growth above $302 million would confirm the bull case.
Bear confirmed if
An EPS worse than $-1.65 would confirm the bear case.
What the market is pricing for the move.
Implied Move
±16.34%
Historical Avg
±11.3%
The options market is pricing in a significant potential movement in the stock, indicating that investors are anticipating volatility around the earnings report.
Options are pricing ±13.7% while INSM has averaged ±11.3% over the last 8 prints — setup is pricing rich.
ATM IV
1.0%
30d HV
46.5%
Smart-money positioning from the most recent 13F filings.
Institutional
105.05%
of float
Insider
0.51%
of float
Holders
970
institutions
Top Holders· as of Jun 2026
FMR, LLC
16,143,583 sh · $1.6B
7.39%
22.7%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Insmed beats expectations, history suggests a potential average one-day move of +1.46%, confirming a positive outlook.
In line / cautious
If results are in line with expectations but management provides cautious commentary, the stock may see muted movement as investors reassess their outlook.
Miss
Should the company miss expectations again, history suggests an average one-day move of +1.98%, indicating that the market may react negatively.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
0 buys·1 sell
Members
1
House only
Est. Notional
$1,001.00–$15,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Blackrock Inc.
15,807,984 sh · $1.6B
7.24%
-5.2%
JPMORGAN CHASE & CO
10,428,170 sh · $1.1B
4.78%
-56.8%
Vanguard Portfolio Management LLC
10,407,962 sh · $1.1B
4.77%
0.3%
Vanguard Capital Management LLC
9,790,865 sh · $996.1M
4.48%
1.5%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net selling
Recent Transactions
Traded Jun 10, 2026 · disclosed Jul 7, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.